firmed by nucleotide sequence analysis. Plasmid pO-Manisa-FG was linearized with NdeI and SpeI. One day before DNA transfection, baby hamster kidney cells that stably expressed T7 RNA polymerase (BHK/T7-9 cells) [13] were seeded on a 48-well plate. At 80%-90% confluency, the cells were transfected with the linearized DNA using Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA). The plaques in LF-BK cells were visualized by staining with a 0.1% crystal violet solution (Fig. 1B ). The recovered virus had a plaque morphology similar to that of the parental virus. Virion purification was performed by sucrose gradient centrifugation. Samples were observed using an electron microscope (Fig. 1B) . The virion purified from the recovered virus had a size of 28 nm, the same as that of the parental virus (Fig. 1B) . Viral particles were released by three successive cycles of freezing and thawing, and the viral titers were determined (Fig. 1C) .
To further compare the growth characteristics of the pare ntal virus and the viruses derived from recombinant plasmids, the growth kinetics of these viruses were examined. We compared the replication in various cells of the field strain of the FMDV and the O Manisa-FG virus produced in vitro. Among various cell lines, the best replication was observed in the BHK-21 and LF-BK cells (Fig. 1C) . Twenty-four hours after inoculating the cells, the growth potency of most viruses increased to the highest level in the BHK-21 and LF-BK cells. No major difference in growth potency was observed between the two viruses in the BHK-21 cell, which is used as an antigenproducing cell for vaccine manufacture. The O Manisa-FG showed slight low titers compared to the parental virus until 20 hours after infection, but a similar titer was shown at 24 hours (Fig. 1C) .
The difference of the genes between the virus recovered from full-length cDNA genome produced in vitro (O Manisa-FG) and the parental virus (O Manisa-PV) was that the poly(C) tract and poly(A) tail were longer than that of the field strain (GenBank accession No. AY593823) by three nucleotides (nt) respectively, which was inserted in the O Manisa-FG. The O Manisa-FG in full genome analysis had differences of five amino acids (K765T, E807K, S858C, and K934E in VP1, T1565E in 3A of polyprotein) or twenty-one nucleotides (T21C, T124C,  C545T, A580C, T585A, G586A, and C804T in 5´ untranslated  region [UTR], G2178A, C2520T, A3392C, G3517A, A3670T,  T3831C, A3898G, A4170G, A5791T, T6585C, T6873C, G6993A,  and G7464A (Fig. 1D, E) . The VNT was performed according to the manual of diagnostic tests and vaccines for FMD by the World Organization for Animal Health (OIE). Serological relationships between the O Manisa parental and recovered virus showed a high r1 value (0.85-1.11) ( Table 1 ). The result from the matching test showed that O Manisa vaccine might protect against ME-SA and SEA topotypes, in case of use of high potency vaccine, even though r1 accuracy is substantially low. O Manisa has been widely used for protection against the ME-SA and SEA topotype. The 2010-2011 outbreaks of the SEA topotype in Japan and South Korea occurred on a large scale and inflicted considerable economic damage by infecting many animals. During this time, the O Manisa vaccine was used to rapidly control the outbreak of FMD in Korea and Japan.
The most important genetic difference between the field strain and the recombinant virus prepared by this study is the r1 values were calculated by division between reciprocal arithmetic titers (serum antibody titer against viruses using for VNT/serum antibody titer against vaccine viruses in the vaccination groups). This experiment was repeatedly tested three times. length of the poly(C) tract. The natural poly(C) tract of the field strain FMDV is 100-420 nt [14] , which is very long and difficult to artificially reconstruct and insert. This suggests that the poly(C) tract has very diverse effects on the replication, and that the virus with a large number of poly(C) generally shows higher replication. The length of the poly(A) tail also affects the stability of viral RNA [15] . The length of the poly(A) tail can influence infectivity, but similar results were obtained with 10 nt and 40 nt [16] . Therefore, the addition of over 10 nt would show no big differences in replication. The O Manisa-FG that we manufactured had 15 nt for the poly(C) tract, and 20 nt for the poly(A) tail, and the virus had a titer of about 10 7.0 TCID50/mL. If virus titer were to later decrease due to the insertion or removal of marker genes, we could overcome this problem by adjusting the length of the poly(C) tract or the poly(A) tail or replacing 3D polymerase. Until now, FMD vaccines have been produced by inactivating virulent viruses. However, the trend taken in recent developments of the FMD vaccine is to insert or remove markers through recombination of the vaccine seed virus to differentiate it from the field strain, to improve the stability of the capsid antigen, and to develop viruses with the virulence removed [14] . Through animal experiments conducted according to the guidelines of the Animal and Plant Quarantine Agency (QIA) in Korea, we found no pathogenesis of O Manisa-FG in mice, pigs or dairy goats escaping via the leaking problem in mass culture (Table 2) . However, neutralizing antibodies in the animals was raised 5-6 days after challenge by intradermal (0.1 mL) or intramuscular routes (1 mL) of 10 5.0 TCID50/0.1 mL. The formation of antibodies in the challenged animals seems to show ability of the virus to replicate without virulence ( Fig. 1D-F) .
In the future, the utilization of O Manisa as a safe vaccine strain will increase if recombinant viruses can be manipulated by inserting or removing a marker gene for differential serology or replacing the protective gene from another serotype. Clinical score was determined by adding the following points: an elevated body temperature of 40°C (1 point), 40.5° (2 points), or 41° (3 points); reduced appetite (1 point) or no food intake and food left over from the day before (2 points); lameness (1 point) or reluctance to stand (2 points); presence of heat and pain after palpation of the coronary band (1 point) or not standing on the affected foot (2 points); vesicles on the feet dependent on the number of feet affected and with a maximum of 4 points; visible mouth lesions on the tongue (1 point), gums or lips (1 point), or snout (1 point), for a maximum of 3 points.
b)
Lesion detected only on the injected foot site.
